

PII: S0040-4020(96)01173-8

An Efficient and General Method for the Synthesis of 3-Phosphorylated 4-Aminoquinolines from β-Phosphine Oxide and Phosphonate Enamines.

Francisco Palacios*, Domitila Aparicio, Jesús García.

Departamento de Química Orgánica. Facultad de Farmacia. Universidad del País Vasco. Apartado 450. 01080 Vitoria. SPAIN.

Abstract: An easy and efficient synthesis of 4-aminoquinolines substituted with a phosphine oxide 1, phosphine sulphide 13 and phosphonate 11 group in the 3-position is described. The key step is a regioselective addition of lithiated β -enamino phosphine oxides 2 and phosphonate $\underline{6}$ to isocyanate and isothiocyanates to give functionalized amides $\underline{7}$, $\underline{8}$ and thioamide 12. Subsequent cyclization of these compounds with phosphorus oxychloride in the presence of triethylamine afforded the substituted 4-aminoquinolines $\underline{1}$, $\underline{11}$ and $\underline{13}$, \bigcirc 1997 Elsevier Science Ltd. All rights reserved.

Quinoline ring systems represent an important class of compounds¹ and have attracted a great deal of attention in recent years because they constitute the backbone of a wide group of biologically active products such as alkaloids^{1,2a} and azasteroids.^{2b} Furthermore, the utility of 4-amino substituted quinolines has been recently demonstrated convincingly given that these compounds have interesting pharmacological properties and are widely used in medicinal chemistry. Amodiaquine \underline{I} displays antimalarial activity,³ while Dequalinium analogues II are potent and selective K⁺ channel blockers.⁴ 4-Arylaminoquinoline SK&F 96067 III has recently applied to the treatment of ulcers and related gastric disorders⁵ (Scheme 1). Likewise, 4-aminoquinolines have been used as antiinflammatory^{6a} and antihypertensive agents,^{6b} as non-nucleoside HIV-1 inhibitors⁷ and as reversible inhibitors of (H^+/K^+) -ATPase.^{5,8} In these types of 4-aminoquinolines the presence of a carbonyl (see compound III, Scheme 1) or an ester group in the position 3 seems to play a key role in establishing the orientation of the arylamino group and therefore in the biological activity of these compounds.^{5,8} With this in mind, we are interested in the design of new aminoquinoline derivatives substituted with a phosphine oxide, a phosphine sulphide or a phosphonate group in the 3 position of the heterocyclic system. These substitutents could regulate important biological functions and could increase the biological activity of these type of compounds, in a similar way to that reported for other pharmaceuticals.⁹ Furthermore, we assume that, in 4-aminoquinolines, the phosphoryl group, a phosphorus isosteric analogue of the carbonyl group, might be responsible for fixing the conformation about the 4-arylamino moiety through a combination of *intra* molecular hydrogen-bonding and π -electron delocalization.



While there are many approaches available for quinoline derivatives, ^{1a} synthetic routes to 4aminoquinolines are relatively few and most of them involve nucleophilic displacement of the chlorine atom of 4-chloroquinoline. ^{1a,5,10} (Scheme 2, *route a*) Likewise, 4-aminoquinolines can alternatively be prepared by tandem reactions that involve simultaneously both the construction of the quinoline ring and the introduction of the amino group in the position 4 (see Scheme 2, *route b*) such as been reported when functionalized amines, ^{11a} imines, ^{11b,c} enamines^{11d-h} and carbodiimides^{11i,j} have been used.



In connection with our interest in the synthesis of five¹² and six¹³ membered phosphorylated nitrogen heterocycles we have used β -functionalized enamines derived from phosphazenes, phosphonium salts, phosphine oxides and phosphonates as synthetic intermediates in the synthesis of acyclic derivatives such as oximes^{14a} allylamines,^{14b} hydrazones,^{14c} azadienes^{14d} and aminodienes^{14e} as well as phosphorus containing heterocycles.¹⁵ In this context, we have recently described the synthesis of β -enamines derived from phosphine oxides and phosphonates and the use of these compounds as homologation reagents for the conversion of carbonyl derivatives into allylamines.¹⁶ A recent publication,¹⁷ reporting an excellent method for synthesis of aminoquinoline SK&F96067 (III, Scheme 1) has prompted us to report our own results concerning the preparation of 3-phosphorylated 4-aminoquinolines <u>1</u> from easily available starting material such as arylamines, isocyanates and phosphorylated allenes <u>4</u> (Scheme 2). Therefore, here we aim to extend the synthetic use of phosphorylated enamines <u>3</u> (R= Ph, OEt) in the preparation of substituted 4aminoquinolines <u>1</u> containing phosphine oxide and phosphonate groups in the 3-position. Retrosynthetically, we envisaged obtaining quinolines $\underline{1}$ by insertion of both a carbon atom and the amino group between the *ortho*-position of the aryl group and the enaminic carbon atom of functionalized compound $\underline{3}$ (Scheme 2). A tandem combination of isocyanates and phosphorus oxychloride was used and the key step in this synthetic methodology involved the regioselective reaction of metallated enamines $\underline{3}$ with isocyanates.

RESULTS AND DISCUSSION

Reaction of metallated enamines derived from phosphine oxides 5 and phosphonates 6 with isocyanates.

Enamines $\underline{5}$ (R²= H), easily prepared by simple addition of amines to phosphine oxide allenes, ¹⁶ were treated with methyllithium in tetrahydrofuran followed by addition of isocyanates (*TLC* control) and aqueous work-up giving polyfunctionalized phosphine oxides $\underline{7}$ in high yield (table 1, entries 1-7). Compounds $\underline{7}$ were characterized on the basis of their spectroscopic data, which indicate that they are isolated as the enamino tautomer $\underline{7}$. Thus, the ³¹*P*-*NMR* spectrum of $\underline{7a}$ showed absorption at δ_{P} = 36.8 ppm and in the ¹*H*-*NMR* spectrum of this derivative $\underline{7a}$ the methyl group gave a singlet at δ_{H} = 1.48, and the enamine and imide protons resonates at δ_{H} = 11.68 and 13.72 ppm, while the ¹³*C*-*NMR* spectrum showed absorptions at δ_{C} = 83.3 (¹*J*_{*PC*}= 115.8 Hz) for the carbon bonded to phosphorus as well a doublet at 22.0 ppm (³*J*_{*PC*}= 6.0 Hz) assignable to the methyl group of the *E*-isomer.^{14b}c,16





The substitution in the starting enamine $\underline{5}$ seems to play an important role in this process since when enamines $\underline{5}$ are substituted by an alkyl group (R²= CH₃) a mixture of Z and E enamines $\underline{7}$ (table 1, entries 8,9) was obtained, whereas when enamines $\underline{5}$ are substituted by an aryl group (R²= p-CH₃-C₆H₄) a mixture of not only Z- and E-enamines $\underline{7}$ but also the β -iminophosphine oxide $\underline{7'}$ was obtained (table 1, entry 10), although for our subsequent purposes the separation of the enamines and imines is not necessary. In ¹H-NMR the imine $\underline{7'}$, for example, showed clearly different absorptions related to the enamine tautomer $\underline{7}$, namely a doublet at δ_{H} = 4.73 ppm (¹J_{PC}= 15.4 Hz) for the methine protons, and in the ¹³C-NMR spectrum the methine carbon showed an absorption at δ_{C} = 56.4 ppm (¹J_{PC}= 51.1 Hz), while in the ¹³C-NMR spectrum of $\underline{7}$ the absorption of the carbon bonded to phosphorus was shifted to lower field (δ_{C} = 85.4 and 95.9 ppm for E- and Z-isomers) relative to those of the imine compound $\underline{7'}$. Furthermore, in this case the ³¹P-NMR spectrum of the mixture $\underline{7j/7'}$ showed three different absorptions at δ_{P} = 35.6, 35.0 and 31.5 ppm in an approximate isomer ratio 33/33/34 as evidenced by the relative peak areas for each compound, in which the high-field chemical shift corresponds to the imine compound **<u>7'j</u>**. Similarly, the enamine derived from phosphonate ester **<u>6</u>** reacted with phenylisocyanate and gave β -functionalized phosphonate **<u>8</u>** in very high yield (table 1, entry 11).

Entry	Compound	R ¹	R ²	<u>R³</u>	Yield (%) ^a	Ratio(7:7')b	m.p. (°C)
1	7a	Н	Н	Ph	76	100:0	124-126
2	7b	<i>p</i> -Me	Н	Ph	72	100:0	85-87
3	7c	p-MeO	Н	Ph	83	100:0	77-80
4	7d	o-MeO	Н	o-MePh	77	100:0	85-87
5	7e	3,4-(Me) ₂	Н	Ph	74	100:0	86-88
6	7f	o-Br	Н	Ph	71	100:0	85-88
7	7g	m-Cl	Н	Ph	76	100 : 0	82-84
8	7h	Н	Me	Ph	81	100 ^c : 0	130-132
9	7 i	<i>p</i> -Me	Me	Ph	78	100 ^d : 0	168-170
10	7j	<i>p</i> -Me	p-MePh	Ph	72	66 ^e : 34	137-140
11	8	H	<u>H</u>	Н	74	100:0	85-86

Table 1. Functionalized phosphine oxides 7/7' and phosphonate **8** obtained.

^aYield of isolated product <u>7/7</u>, and <u>8</u> based on <u>5</u>, <u>6</u>. ^bEnamino/imino and Z/E ratio determinated by ³¹P-NMR, ^cZ/E ratio (33/67). ^dZ/E ratio (32/68). ^eZ/E ratio (33/33).

Preparation of substituted 4-aminoquinolines from phosphine oxide 7 and phosphonate derivatives 8.

Treatment of functionalized enamines $\underline{7}$ with phosphorus oxychloride in the presence of triethylamine led to the formation of aminoquinolinylphosphine oxides $\underline{1}$ (Scheme 4) in excellent yield (table 2, entries 1-7). Spectroscopic data were in agreement with the assigned structure. Mass spectrometry of $\underline{1a}$ showed the molecular ion peak (m/z 434, 100 %), while the methyl group gave ¹H resonance at δ_{H} = 2.04 ppm. The formation of substituted quinolines $\underline{1}$ can be assumed to proceed via 6π -electrocyclization of conjugated imidoyl ketene imines $\underline{10}$ formed by the reaction of functionalized enamines $\underline{7}$ with phosphorus oxychloride in a similar way to that previously reported. ^{11b,17}

Formation of aminoquinolines were observed not only when enamines $\underline{7}$ were used, but also when a mixture of the Z- and E-enamines $\underline{7}$ and the imine-tautomers $\underline{7}$ was used as starting material (Table 2, entries 8-10). The scope of this reaction was not limited to phosphine oxide derivatives $\underline{7}$, since the enamine derived from phosphonate ester $\underline{8}$ also reacted with phosphorus oxychloride in the presence of triethylamine and gave in excellent yield the 4-aminoquinoline containing a phosphate group in 3 position $\underline{11}$ (Table 2, entry 11). From a preparative point of view it is noteworthy that the synthesis of phosphorylated 4-aminoquinolines $\underline{1}$ does not require the isolation and purification of functionalized phosphine oxides $\underline{7}$ and phosphonate $\underline{8}$ and they can be obtained in "one pot" reaction from the enamines derived from phosphine oxides $\underline{5}$ and phosphonate $\underline{6}$ when these compounds are directly metallated with methyllitium in *THF* with subsequent addition of isocyanates phosphorus oxychoride and aqueous work-up.

Entry	Compound		R ²	R ³	Yield (%) ^a	m.p. (°C)
1	1a	Н	Н	Ph	78(67) ^b	188-190
2	1b	6-Me	Н	Ph	72(62) ^b	218-220
3	1c	6-MeO	Н	Ph	71	191-192
4	1d	8-MeO	Н	o-MePh	74	197-199
5	1e	6,7-(Me) ₂	Н	Ph	64	245-247
6	1f	8-Br	Н	Ph	66	215-218
7	1g	7-Cl	Н	Ph	69	207-208
8	1h	Н	Me	Ph	76	169-171
9	1i	6-Me	Me	Ph	71	196-197
10	1j	6-Me	<i>p</i> -MePh	Ph	63	152-153
11	11	Н	Н	Ph	77 ^c (65) ^d	101-103
12	13	6-Me	H	Ph	72 ^e	152-155

Table 2. 4-A minoquinolines 1, 11 and 13 obtained.

^a Yield of isolated product <u>1</u> based on <u>7</u>. ^bYield of isolated product <u>1</u> in "one pot" reaction from <u>5</u>. ^cYield of isolated product <u>11</u> based on <u>8</u>. ^dYield of isolated product <u>11</u> in "one pot" reaction from <u>6</u>. ^eYield of isolated product <u>13</u> based on <u>12</u>.



Scheme 4

Synthesis of 4-aminoquinolines derived from phosphine sulphides 13.

This methodology used for the preparation of aminoquinolines 1 can also be applied to the synthesis of 4-aminoquinolines derived from phosphine sulphides 13 when isothiocyanates are used instead of isocyanates. Metallation of β -enamino phosphine oxides 5 with methyllitium in tetrahydrofuran followed by addition of isothiocyanates (*TLC* control) and aqueous work-up afforded the functionalized thioamide 12.

Treatment of thioamides $\underline{12}$ with phosphorus oxychloride in the presense of triethylamine gave aminoquinolinyl phosphine sulphides $\underline{13}$ (Scheme 5). Formation of these compounds $\underline{13}$ could be explained

by a similar process to that mentioned in Scheme 4, although with a spontaneous exchange of oxygen for sulphur, with transformation of phosphine oxide into the phosphine sulphide group, caused by the reaction conditions.



In conclusion, we describe an easy and efficient method for synthesis of 4-aminoquinolines substituted with a phosphine oxide 1, a phosphonate 11 and a phosphine sulphide 13 group in 3-position from readily available starting materials such as arylamines, allenes and isocyanates or isothiocyanates (see Scheme 2) and under mild reaction conditions. 4-Aminoquinolines are useful compounds in medicinal chemistry since these products display a broad range of biological activities and have been widely used as pharmaceuticals.³⁻⁸

ACKNOWLEDGEMENTS

The present work has been supported by the Dirección General de Investigación Científica y Técnica (DGICYT, PB93-0501) and by the Universidad del País Vasco (UPV, 012-95). J. García thanks the Ministerio de Educación y Ciencia for a Predoctoral Fellowship.

EXPERIMENTAL SECTION

General. Melting points were determined with a Buchi SPM-20 apparatus and are uncorrected. Analytical *TLC* was performed on 0.25mm silica gel plates (Merck). Visualization was accomplished by *UV* light and iodine. Solvents for extraction and chromatography were technical grade and distilled from the indicated drying agents: $CH_2Cl_2(P_2O_5)$; *n*-hexane and diethyl ether (sodium benzophenone ketyl); ethyl acetate (K_2CO_3). All solvents used in reactions were freshly distilled from appropriate drying agents before use: acetonitrile (P_2O_5); $CHCl_3(P_2O_5)$. All other reagents were recrystallized or distilled as necessary. Column (flash) chromatography was carried out on silica gel (Merck, 70-230 mesh). Mass spectra were obtained on a Hewlett Packard 5890 spectrometer. Infrared spectra were taken on a Nicolet IRFT Magna 550 spectrometer. ^{1}H -NMR spectra were recorded an a Varian 300 MHz spectra were recorded at 75 MHz with chloroform (77.0 ppm) as an internal reference in $CDCl_3$ solutions. ^{13}C -NMR spectra were recorded at 120 MHz with 85% phosphoric acid as an external reference. Elemental analyses were performed in a Perkin Elmer Model 240 instrument. Chemical shifts are given in ppm (δ); multiplicities are indicated by s (singlet), d (doublet), duriplet) q (quadruplet) or m (multiplet). Coupling constants, J, are reported in hertz. Infrared spectra (*IR*) were obtained as neat liquids, or as solids in *KBr*. Peaks are reported in cm⁻¹. Mass spectra (*EI*) were performed in oven (125 °C) or flame-dried glassware under an inert atmosphere of dry N₂.

General procedure for the reaction of enamino carbanions derived from phosphine oxides 5 and phosphonate 6 with isocyanates or isothiocyanates. A dry flask, 100-mL, 2-necked, fitted with a dropping funnel, gas inlet, and magnetic stirrer, was charged with 5 mmol of β -enamino phosphine oxides 5 and phosphonates 6 and 20 mL of *THF*. The temperature was allowed to descend to 0 °C and a solution (5.5 mmol) of methyllithium in *THF* was then added. The mixture was allowed to stir for 1 h. A solution (5 mmol) of isocyanate or isothiocyanate in 10 mL of *THF* was added at this temperature. The mixture was stirred until *TLC* indicated the disappearance of the compound 5 or 6 (~ 16 h). The mixture was washed with water and extracted with *CH*₂*Cl*₂. The organic layers were dried over *MgSO*₄, filtered and concentrated. The crude product was purified by recrystallization from diethyl ether.

E-1-Phenylamide-2-(*N*-phenylamino)prop-1-enyldiphenylphosphine oxide (<u>7a</u>). 1717 mg (76 %) of <u>7a</u> as a white solid. Data for <u>7a</u>: mp 124-126 °C; ¹*H*-*NMR* (300 MHz) 1.48 (s, 3H, CH₃), 6.93-7.83 (m, 20H, arom), 11.68 (s, 1H, NH), 13.72 (s, 1H, NH); ${}^{13}C$ -*NMR* (75 MHz) 22.0 (d, {}^{3}JPC= 6.0 Hz, CH₃), 83.3 (d, {}^{1}JPC\approx 115.8 Hz, C-P), 118.7-138.8 (C-arom), 165.3 (d, {}^{2}JPC= 17.1 Hz), 170.2 (d, {}^{2}JPC= 11.0 Hz); {}^{31}P-*NMR* (120 MHz) 36.8; *IR* (*KBr*) 3254, 3053, 1602, 1548, 1490, 1132 cm⁻¹; *MS* (EI) 452 (M⁺, 10). Anal. Calcd for C_{28H25N2O2}P: C, 74.34; H, 5.53; N, 6.19. Found: C, 74.55; H, 5.38; N, 6.25.

E-1-Phenylamide-2-(*N*-*p*-tolylamino)prop-1-enyldiphenylphosphine oxide (\underline{Tb}). 1678 mg (72 %) of \underline{Tb} as a white solid. Data for \underline{Tb} : mp 85-87 °C; ¹*H*-*NMR* (300 MHz) 1.52 (s, 3H, CH₃), 2.31 (s, 3H, CH₃), 6.93-7.87 (m, 19H, arom), 10.81 (s, 1H, NH), 12.95 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 20.9 (CH₃), 22.1 (d, ³*J*_{*PC*}= 6.2 Hz, CH₃), 83.3 (d, ¹*J*_{*PC*}= 116.3 Hz, C-P), 120.9-139.0 (C-arom), 165.6 (d, ²*J*_{*PC*}= 16.9 Hz), 170.4 (d, ²*J*_{*PC*}= 11.1 Hz); ³¹*P*-*NMR* (120 MHz) 37.5; *IR* (*KBr*) 3433, 3059, 1542, 1439, 1223 cm⁻¹; *MS* (EI) 466 (M⁺, 4). Anal. Calcd for C₂₉H₂₇N₂O₂P: C, 74.68; H, 5.79; N, 6.01. Found: C, 74.75; H, 5.68; N, 6.17.

E-1-Phenylamide-2-(*N*-*p*-methoxyphenylamino)prop-1-enyldiphenylphosphine oxide (7c). 2001 mg (83 %) of 7c as a white solid. Data for 7c mp 78-80 °C; ¹*H*-*NMR* (300 MHz) 1.42 (s, 3H, CH₃), 3.71 (s, 3H, CH₃), 6.75-7.82 (m, 19H, arom), 11.57 (s, 1H, NH), 13.46 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 21.9 (d, ³*J*_{*PC*}= 6.0 Hz, CH₃), 55.3 (O-CH₃), 82.5 (d, ¹*J*_{*PC*}= 116.7 Hz, C-P), 114.2-158.0 (C-arom), 166.1 (d, ²*J*_{*PC*}= 17.6 Hz), 170.3 (d, ²*J*_{*PC*}= 11.1 Hz); ³¹*P*-*NMR* (120 MHz) 37.2; *IR* (*KBr*) 3191, 3054, 1540, 1510, 1247 cm⁻¹; *MS* (EI) 482 (M⁺, 7). Anal. Calcd for C 29H27N2O3P: C, 72.20; H, 5.60; N, 5.81. Found: C, 72.35; H, 5.69; N, 5.97.

E-1-o-Tolylamide-2-(*N*-o-methoxyphenylamino)prop-1-enyldiphenylphosphine oxide (7<u>d</u>). 1909 mg (77%) of 7<u>d</u> as a white solid. Data for 7<u>d</u>: mp 85-87 °C; *^IH-NMR* (300 MHz) 1.42 (s, 3H, CH₃), 2.01 (s, 3H, CH₃), 3.77 (s, 3H, CH₃), 6.75-7.82 (m, 18H, arom), 11.23 (s, 1H, NH), 13.45 (s, 1H, NH); *^{I3}C-NMR* (75 MHz) 17.2 (CH₃), 21.5 (d, ³*J*_{*PC*}= 6.1 Hz, CH₃), 55.2 (O-CH₃), 83.4 (d, ^{*I*}*J*_{*PC*}= 116.6 Hz, C-P), 110.2-158.0 (C-arom), 166.5 (d, ²*J*_{*PC*}= 17.7 Hz), 170.4 (d, ²*J*_{*PC*}= 11.2 Hz); ³¹*P-NMR* (120 MHz) 37.1; *IR* (*KBr*) 3189, 3050, 1533, 1521, 1235 cm⁻¹; *MS* (EI) 496 (M⁺, 3). Anal. Calcd for C₃₀H₂₉N₂O₃P: C, 72.58; H, 5.85; N, 5.64. Found: C, 72.71; H, 5.73; N, 5.67.

E-1-Phenylamide-2-(*N*-3,4-dimethylphenylamino)prop-1-enyldiphenylphosphine oxide (<u>7e</u>). 1678 mg (74 %) of <u>7e</u> as a white solid. Data for <u>7e</u>: mp 86-87 °C; ¹*H*-*NMR* (300 MHz) 1.46 (s, 3H, CH₃), 2.14 (s, 6H, CH₃), 6.76-7.80 (m, 18H, arom), 10.81 (s, 1H, NH), 12.95 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 19.2 (CH₃), 19.7 (CH₃), 22.0 (d,³*J*_{*PC*}= 6.0 Hz, CH₃), 82.6 (d,¹*J*_{*PC*}= 116.8 Hz, C-P), 118.8-138.9 (C-arom), 165.6 (d,²*J*_{*PC*}= 17.1 Hz), 170.4 (d,²*J*_{*PC*}= 10.6 Hz); ³¹*P*-*NMR* (120 MHz) 37.1; *IR* (*KBr*) 3052, 2952, 1542, 1441, 1320 cm⁻¹; *MS* (EI) 480 (M⁺, 8). Anal. Calcd for C₃₀H₂₉N₂O₂P: C, 75.00; H, 6.04; N, 5.83. Found: C, 75.16; H, 6.08; N, 5.91.

E-1-Phenylamide-2-(*N*-o-bromophenylamino)prop-1-enyldiphenylphosphine oxide ($\underline{70}$). 1885 mg (71 %) of $\underline{71}$ as a brown solid. Data for $\underline{71}$ mp 86-88 °C; ^{1}H -*NMR* (300 MHz) 1.35 (s, 3H, CH₃), 6.92-8.25 (m, 19H, arom), 11.62 (s, 1H, NH), 13.60 (s, 1H, NH); ^{13}C -*NMR* (75 MHz) 22.0 (d, $^{3}J_{PC}$ = 6.0 Hz, CH₃), 84.6 (d, $^{1}J_{PC}$ = 118.8 Hz, C-P), 114.8-138.9 (C-arom), 165.0 (d, $^{2}J_{PC}$ = 16.1 Hz), 170.4 (d, $^{2}J_{PC}$ = 10.6 Hz); ^{31}P -*NMR* (120 MHz) 37.3; *IR* (*KBr*) 3352, 3056, 1542, 1441, 1220 cm⁻¹; *MS* (EI) 531 (M⁺-Br, 14). Anal. Calcd for C₂₈H₂₄N₂O₂PBr: C, 63.27; H, 4.52; N, 5.27. Found: C, 63.16; H, 4.38; N, 5.37.

E-1-Phenylamide-2-(*N*-*m*-chlorophenylamino)prop-1-enyldiphenylphosphine oxide (*T*g). 1847 mg (76 %) of *T*g as a brown solid. Data for *T*g: mp 82-84 °C; *^IH-NMR* (300 MHz) 1.51 (s, 3H, CH3), 6.62-7.83 (m, 19H, arom), 11.65 (s, 1H, NH), 13.79 (s, 1H, NH); *^{I3}C-NMR* (75 MHz) 21.9 (d, *³J*_{*PC*} = 6.1 Hz, CH3), 84.8 (d, *¹J*_{*PC*} = 119.0 Hz, C-P), 114.7-139.3 (C-arom), 164.8 (d, *²J*_{*PC*} = 16.1 Hz), 170.0 (d, *²J*_{*PC*} = 10.6 Hz); *³¹P-NMR* (120 MHz) 37.1; *IR* (*KBr*) 3341, 3066, 1595, 1555, 1441, 1220 cm⁻¹; *MS* (EI) 486 (M⁺-Cl, 12). Anal. Calcd for C₂₈H₂₄N₂O₂PCI: C, 69.06; H, 4.93; N, 5.75. Found: C, 69.18; H, 4.78; N, 5.67.

Z- and E-1-Phenylamide-2-(N-phenylamino)but-1-enyldiphenylphosphine oxide (<u>7h</u>). 1887 mg (81 %) of <u>7h</u> as a white solid. Data for <u>7h</u>: mp 130-132 °C; ¹H-NMR (300 MHz) 1.11 (m, 3H, E- and Z-CH₃), 2.16 (m, 2H, E- and Z-CH₂), 6.94-7.82 (m, 20H, arom), 11.66 (s, 1H, NH), 13.65 (s, 1H, NH); ¹³C-NMR (75 MHz) 10.5 (CH₃), 25.1 (d, ³J_{PC}= 9.5 Hz, Z-CH₂), 26.2 (d, ³J_{PC}= 6.1 Hz, E-CH₂), 82.8 (d, ¹J_{PC}= 116.3 Hz, E-C-P), 94.3 (d, ¹J_{PC}= 102.1 Hz, Z-C-P), 118.3-139.6 (C-arom), 167.3 (d. ²J_{PC}= 17.0 Hz), 170.7 (d, ²J_{PC}= 12.7 Hz); ³¹P-NMR (120 MHz) 35.1 and 36.6; IR (KBr) 3161, 1664, 1434, 1162 cm⁻¹; MS (EI) 466 (M⁺, 4). Anal. Calcd for C₂₉H₂₇N₂O₂P: C, 74.68; H, 5.79; N, 6.01. Found: C, 74.82; H, 5.61; N, 5.88.

Z- and E-1-Phenylamide-2-(N_P -tolylamino)but-1-enyldiphenylphosphine oxide ($\underline{7}$), 1872 mg (78 %) of $\underline{7}$ i as a white solid. Data for $\underline{7}$ i: mp 168-170 °C; ${}^{I}H$ -NMR (300 MHz) 1.07 (m, 3H, E- and Z-CH₃), 2.11 (m, 2H, E- and Z-CH₂), 2.24 (s, 3H, E- and Z-CH₃), 6.91-7.87 (m, 19H, arom), 11.69 (s, 1H, NH), 13.35 (s, 1H, NH); ${}^{13}C$ -NMR (75 MHz) 10.3 (CH₃), 20.9 (CH₃), 25.2 (d, ${}^{3}J_{PC}$ = 9.7 Hz, Z-CH₂), 26.0 (d, ${}^{3}J_{PC}$ = 6.0 Hz, E-CH₂), 82.3 (d, ${}^{I}J_{PC}$ = 116.8 Hz, E-C-P), 94.7 (d, ${}^{I}J_{PC}$ = 101.9 Hz, Z-C-P), 119.1-139.7 (C-arom), 169.3 (d, ${}^{2}J_{PC}$ = 17.1 Hz), 171.2 (d, ${}^{2}J_{PC}$ = 13.1 Hz); ${}^{3I}P$ -NMR (120 MHz) 35.0 and 35.6; IR (KBr) 3161, 1664, 1434, 1162 cm⁻¹; MS (EI) 480 (M⁺, 4). Anal. Calcd for C₃₀H₂₉N₂O₂P: C, 75.01; H, 6.04; N, 5.83. Found: C, 75.12; H, 6.11; N, 5.78.

Z- and E-1-Phenylamide-2-(N-p-tolylamino)-3-p-tolylprop-1-enyldiphenylphosphine oxide (7j) and 1-Phenylamide-2-(N-p-tolylimino)-3-p-tolylpropyldiphenylphosphine oxide (7j). 2001 mg (72 %) of 7j/7'j as a white solid. Data for 7j/7'j: mp 138-139 °C; ¹*H*-*NMR* (300 MHz) **Zj**: 2.10 (s, 3H, *E*- and *Z*-CH₃), 2.15 (s, 3H, *E*- and *Z*-CH₃), 3.38 (s, 2H, *E*- and *Z*-CH₂), 6.17-7.93 (m, 23H, arom), 11.59 (s, 1H, NH), 13.21 (s, 1H, NH). **Zj**: 2.18 (s, 3H, CH₃), 2.25 (s, 3H, CH₃), 3.87 (s, 2H, CH₂), 4.73 (d, ²*JpH*= 15.4 Hz, CH-P), 6.17-7.93 (m, 23H, arom), 10.27 (s, 1H, NH); ^{*I*3}*C*-*NMR* (75 MHz) **Zj**: 20.7 (CH₃), 20.8 (CH₃), 35.8 (d, ³*JpC*= 9.0 Hz, *Z*-CH₂), 37.6 (d, ³*JpC*= 6.0 Hz, *E*-CH₂), 85.4 (d, ¹*JpC*= 115.2 Hz, *E*-C-P), 95.9 (d, ¹*JpC*= 102.2 Hz, *Z*-C-P). 119.1-138.7 (C-arom), 165.7 (d,²*JpC*= 13.1 Hz), 166.7 (d,²*JpC*= 7.0 Hz), 167.1 (d,²*JpC*= 17.1 Hz), 170.4 (d,²*JPC*= 11.5 Hz). **Zj**: 20.7 (CH₃), 20.8 (CH₃), 56.4 (d, ¹*JpC*= 51.1 Hz, C-P). 119.1-138.7 (C-arom), 162.5 (d,²*JpC*= 2.5 Hz), 162.8 (d,²*JPC*= 2.0 Hz); ³¹*P*-*NMR* (120 MHz) **Zj**: 35.0 and 35.6. <u>T</u>**j**: 31.5; *IR* (*KBr*) 3161, 1664, 1434, 1162 cm⁻¹; *MS* (EI) 480 (M⁺, 4). Anal. Calcd for C 30H₂9N₂O₂P: C, 75.01; H, 6.04; N, 5.83. Found: C, 75.12; H, 6.11; N, 5.78.

E-1-Phenylamide-2-(*N*-phenylamino)prop-1-enyldiethylphosphonate (8). 861 mg (74 %) of § as a white solid. Data for §: mp 85-86 °C; ^{I}H -*NMR* (300 MHz) 1.28 (t, 6H, $^{3}J_{HH}$ = 7.0 Hz,CH₃), 2.18 (s, 3H, CH₃), 4.09 (m, 4H, CH₂), 6.94-7.53 (m, 10H, arom), 11.38 (s, 1H, NH), 12.65 (s, 1H, NH); ^{I3}C -*NMR* (75 MHz) 16.0 and 16.2 (CH₃), 19.2 (d, $^{3}J_{PC}$ = 3.1 Hz, CH₃), 81.7 (d, $^{I}J_{PC}$ = 196.4 Hz, C-P), 119.1-138.9 (C-arom), 168.8 (d, $^{2}J_{PC}$ = 16.1 Hz), 169.5 (d, $^{2}J_{PC}$ = 19.7 Hz); ^{3I}P -*NMR* (120 MHz) 27.3; *IR* (*KBr*) 3200, 2986, 1542, 1333 cm⁻¹; *MS* (EI) 388 (M⁺, 10). Anal. Calcd for C₂₀H₂₅N₂O4P: C, 61.86; H, 6.43; N, 7.22. Found: C, 61.98; H, 6.38; N, 7.25.

1-Phenylthioamide-2-(*N*-p-tolylimino)propyldiphenylphosphine oxide (12). 1996 mg (83 %) of 12 as a yellow solid. Data for 12: mp 145-146 °C; ¹*H*-*NMR* (300 MHz) 1.78 (s, 3H, CH₃), 2.11 (s, 3H, CH₃), 5.30 (d, ²*J*_{*PH*}=9.1 Hz, CH-P), 6.36-7.94 (m, 19H, arom), 10.51 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 20.8 (CH₃), 22.5 (CH₃), 68.2 (d, ¹*J*_{*PC*}=47.3 Hz, C-P), 119.3-138.9 (C-arom), 165.5 (C=N), 189.1 (C=S); ³¹*P*-*NMR* (120 MHz) 30.3; *IR* (*KBr*) 3174, 3005, 1592, 1513, 1373, 1149 cm⁻¹; *MS* (EI) 482 (M⁺, 17). Anal. Calcd for C₂₉H₂₇N₂OSP: C, 72.21; H, 5.60; N, 5.81. Found: C, 72.45; H, 5.48; N,5.75.

General procedure for the preparation of the phosphorylated quinolines 1, 11 and 13. A dry flask, 100-mL, 2-necked, fitted with a dropping funnel, gas inlet, and magnetic stirrer, was charged with (3 mmol) of amide 7, 8 or thioamide 12, 0.55 mL (4 mmol) of triethylamine and 15 mL of *THF*. A solution 0.30 mL (3.2 mmol) of phosphorus oxychloride and 10 mL of *THF* was added over 10 min. The mixture was stirred and refluxed until *TLC* indicated the disappearance of the compound 7, 8 or 12 (~2 days). The mixture was diluted with 30 mL water and extracted with CH_2Cl_2 (3 x 15). The CH_2Cl_2 layers were washed with water. The combined organic layers were dried over $MgSO_4$, filtered, and concentrated. The crude product was purified by flash-chromatography on silica gel (hexane/diethyl ether, 1/1). Quinolines can also be obtained in "one pot" reaction: 4 mmol of 5 in 20 mL of *THF* was added at this temperature. The mixture was stirred for 2 4 h, and a solution of 0.39 mL (4.2 mmol) of phosphorus oxychloride and 10 mL of *THF* was added. The quinoline was purified as described above.

3-Diphenylphosphoryl-2-methyl-4-phenylaminoquinoline (<u>1a</u>). 1015 mg (78 %) of <u>1a</u> as a yellow solid. Data for <u>1a</u>: mp 188-190 °C; ¹*H*-*NMR* (300 MHz) 2.04 (s, 3H, CH₃), 7.04-7.80 (m, 19H, arom), 10.96 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 28.4 (CH₃), 106.7 (d, ¹*J_{PC}*= 98.2 Hz, C-P), 119.9-158.4 (C-arom); ³¹*P*-*NMR* (120 MHz) 38.7; *IR* (*KBr*) 3200, 3059, 1568, 1400, 1118 cm⁻¹; *MS* (EI) 434 (M⁺, 100). Anal. Calcd for C28H23N2OP: C, 77.42; H, 5.30; N, 6.45. Found: C, 77.61; H, 5.53; N, 6.55.

3-Diphenylphosphoryl-2,6-dimethyl-4-phenylaminoquinoline (<u>1b</u>). 968 mg (72 %) of <u>1b</u> as a yellow solid. Data for <u>1b</u>: mp 218-220 °C; ¹*H-NMR* (300 MHz) 2.02 (s, 3H, CH₃-C=N), 2.18 (s, 3H, CH₃), 6.70-7.73 (m, 18H, arom), 10.84 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 21.9 (CH₃), 28.2 (CH₃), 107.0 (d, ¹*J_{PC}*= 99.1 Hz, C-P), 120.1-157.7 (C-arom); ³¹*P-NMR* (120 MHz) 38.2; *IR* (*KBr*) 3261, 3059, 1609, 1575, 1179 cm⁻¹; *MS* (EI) 448 (M⁺, 88). Anal. Calcd for C₂₉H₂₅N₂OP: C, 77.68; H, 5.58; N, 6.25. Found: C, 77.51; H, 5.69; N, 6.51.

3-Diphenylphosphoryl-2-methyl-6-methoxy-4-phenylaminoquinoline (<u>1c</u>). 988 mg (71 %) of <u>1c</u> as a yellow solid. Data for <u>1c</u>: mp 191-192 °C; ¹*H-NMR* (300 MHz) 2.01 (s, 3H, CH₃-C=N), 3.33 (s, 3H, CH₃-O), 6.72-7.73 (m, 18H, arom), 10.82 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 28.0 (CH₃), 54.8 (CH₃-O), 107.3 (d, ¹*J*_{*PC*} = 98.2 Hz, C-P), 104.7-156.9 (C-arom); ³¹*P-NMR* (120 MHz) 38.6; *IR* (*KBr*) 3113, 3027, 1568, 1491, 1238 cm⁻¹; *MS* (EI) 464 (M⁺, 88). Anal. Calcd for C29H₂5N₂O₂P: C, 75.01; H, 5.39; N, 6.03. Found: C, 75.23; H, 5.54; N, 6.11.

3-Diphenylphosphoryl-2-methyl-8-methoxy-4-*o***-tolylaminoquinoline** (<u>1</u>*d***).** 1061 mg (74 %) of <u>1</u>*d* as a yellow solid. Data for <u>1</u>*d*: mp 197-199 °C; ¹*H*-*NMR* (300 MHz) 2.02 (s, 3H, CH₃-C=N), 2.16 (s, 3H, CH₃), 3.37 (s, 3H, CH₃-O), 6.69-7.63 (m, 17H, arom), 10.67 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 25.4 (CH₃), 28.0 (CH₃), 54.6 (CH₃-O), 106.9 (d, ¹*JPC*= 98.0 Hz, C-P), 104.3-157.5 (C-arom); ³¹*P*-*NMR* (120 MHz) 38.5; *IR* (*KBr*) 3121, 3019, 1561, 1482, 1223 cm⁻¹; *MS* (EI) 478 (M⁺, 88). Anal. Calcd for C₃₀H₂₇N₂O₂P: C, 75.31; H, 5.65; N, 5.86. Found: C, 75.43; H, 5.52; N, 5.91.

3-Diphenylphosphoryl-2,6,7-trimethyl-4-phenylaminoquinoline (<u>1e</u>). 887 mg (64 %) of <u>1e</u> as a yellow solid. Data for <u>1e</u>: mp 245-247 °C; ¹*H-NMR* (300 MHz) 2.04 (s, 3H, CH₃-C=N), 2.11 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 6.74-7.75 (m, 17H, arom), 10.84 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 19.9 (CH₃), 20.2 (CH₃), 28.2 (CH₃), 106.1 (d, ¹*J_{PC}*= 99.7 Hz, C-P), 118.3-157.4 (C-arom); ³¹*P-NMR* (120 MHz) 38.4; *IR* (*KBr*) 3269, 2978, 1712, 1594, 1430, 1115 cm⁻¹; *MS* (EI) 462 (M⁺, 95). Anal. Calcd for C₃₀H₂₇N₂OP: C, 77.92; H, 5.84; N, 6.06. Found: C, 77.71; H, 5.72; N, 6.14.

8-bromo-3-Diphenylphosphoryl-2-methyl-4-phenylaminoquinoline (<u>1f</u>). 1016 mg (66 %) of <u>1f</u> as a yellow solid. Data for <u>1f</u>: mp 215-218 °C; ¹*H*-*NMR* (300 MHz) 2.09 (s, 3H, CH₃), 6.71-7.90 (m, 18H, arom), 11.03 (s, 1H, NH); ¹³C-*NMR* (75

MHz) 27.6 (CH₃), 107.4 (d, ¹*J*_{PC}= 98.6 Hz, C-P), 117.2-152.2 (C-arom); ³¹*P*-*NMR* (120 MHz) 38.8; *IR* (*KBr*) 3341, 3294, 1649, 1552, 1238 cm⁻¹; *MS* (EI) 513 (M⁺, 98). Anal. Calcd for C₂₈H₂₂N₂OPBr: C, 65.50; H, 4.29; N, 5.46. Found: C, 65.61; H, 4.33; N, 5.35.

7-chloro-3-Diphenylphosphoryl-2-methyl-4-phenylaminoquinoline (**1g**). 969 mg (69 %) of **1g** as a yellow solid. Data for **1g**: mp 207-208 °C; ¹*H-NMR* (300 MHz) 2.11 (s, 3H, CH₃), 6.77-7.94 (m, 18H, arom), 10.95 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 26.6 (CH₃), 106.5 (d, ¹*J*_{*PC*}= 99.1 Hz, C-P), 116.5-152.9 (C-arom); ³¹*P-NMR* (120 MHz) 39.1; *IR* (*KBr*) 3365, 3094, 1633, 1542, 1211 cm⁻¹; Anal. Calcd for C₂₈H₂₂N₂OPCl: C, 71.79; H, 4.70; N, 5.98. Found: C, 71.90; H, 4.63; N, 5.85.

3-Diphenylphosphoryl-2-ethyl-4-phenylaminoquinoline (1h). 1021 mg (76 %) of **1h** as a yellow solid. Data for **1h**: mp 169-171 °C; ^{1}H -NMR (300 MHz) 0.58 (t, 3H, $^{3}J_{HH}$ = 7.2 Hz, CH 3), 2.40 (q, 2H, $^{3}J_{HH}$ = 7.2 Hz, CH 2), 6.75-7.98 (m, 19H, arom), 11.05 (s, 1H, NH); ^{13}C -NMR (75 MHz) 12.8 (CH3), 32.9 (CH2), 105.7 (d, $^{1}J_{PC}$ = 99.7 Hz, C-P), 119.0-163.2 (C-arom); $^{3}I_{P}$ -NMR (120 MHz) 39.7; IR (KBr) 3335, 3056, 1602, 1568, 1407, 1125 cm⁻¹; MS (EI) 448 (M⁺, 97). Anal. Calcd for C₂₉H₂₅N₂OP: C, 77.68; H, 5.58; N, 6.25. Found: C, 77.78; H, 5.73; N, 6.20.

3-Diphenylphosphoryl-2-ethyl-6-methyl-4-phenylaminoquinoline (11). 984 mg (71 %) of **1i** as a yellow solid. Data for **1i**: mp 196-197 °C; ¹*H-NMR* (300 MHz) 0.57 (t, 3H, ³*J*_{*HH*}= 7.3 Hz, CH₃), 2.19 (s, 3H, CH₃), 2.38 (q, 2H, ³*J*_{*HH*}= 7.3 Hz, CH₂), 6.72-7.75 (m, 18H, arom), 11.00 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 12.9 (CH₃), 21.6 (CH₃), 32.8 (CH₂), 106.0 (d, ¹*J*_{*PC*}= 99.2 Hz, C-P), 119.8-162.2 (C-arom); ³¹*P-NMR* (120 MHz) 38.7; *IR* (*KBr*) 3046, 2989, 1593, 1414, 1114 cm⁻¹; *MS* (EI) 462 (M⁺, 100). Anal. Calcd for C₃₀H₂₇N₂OP: C, 77.92; H, 5.84; N, 6.06. Found: C, 77.75; H, 5.76; N, 6.21.

3-Diphenylphosphoryl-2-(*p*-tolylmethyl)-6-methyl-4-phenylaminoquinoline (1j). 1017 mg (63 %) of 1j as a yellow solid. Data for 1j: mp 152-153 °C; ¹H-NMR (300 MHz) 2.26 (s, 3H, CH₃), 2.30 (s, 3H, CH₃), 3.92 (s, 2H, CH₂), 6.48-7.86 (m, 22H, arom), 10.76 (s, 1H, NH); ¹³C-NMR (75 MHz) 20.8 (CH₃), 21.6 (CH₃), 43.8 (CH₂), 108.8 (d, ¹J_{PC}= 97.7 Hz, C-P), 108.0-158.8 (C-arom); ³¹P-NMR (120 MHz) 37.6; IR (KBr) 3205, 3063, 1693, 1487, 1412 cm⁻¹; MS (EI) 538 (M⁺, 100). Anal. Calcd for C 36H₃1N₂OP: C, 80.30; H, 5.76; N, 5.20. Found: C, 80.15; H, 5.66; N, 5.31.

3-Diethylphosphonate-2-methyl-4-phenylaminoquinoline (<u>11</u>). 855 mg (77 %) of <u>11</u> as a yellow solid. Data for <u>11</u>: mp 101-103 °C; ¹*H-NMR* (300 MHz) 1.27 (t, 6H, ³*J*_{*HH*}= 6.9 Hz, CH₃), 2.78 (s, 3H, CH₃), 3.97-4.10 (m, 4H, CH₂), 6.82-7.83 (m, 9H, arom), 10.39 (s, 1H, NH); ¹³*C-NMR* (75 MHz) 16.1 (CH₃), 26.3 (CH₃), 62.3 (CH₂), 103.9 (d, ¹*J*_{*PC*}= 178.8 Hz, C-P), 119.4-160.1 (C-arom); ³¹*P-NMR* (120 MHz) 22.4; *IR* (*KBr*) 3241, 2985, 1602, 1488, 1407, 1031 cm⁻¹; *MS* (EI) 370 (M⁺, 100). Anal. Calcd for C₂₀H₂₃N₂O₃P: C, 64.86; H, 6.21; N, 7.57. Found: C, 64.78; H, 6.13; N, 7.70.

3-Diphenylthiophosphoryl-2,6-dimethyl-4-phenylaminoquinoline (13). 1002 mg (72 %) of 13 as a yellow solid. Data for 13: mp 152-155 °C; ¹*H*-*NMR* (300 MHz) 2.05 (s, 3H, CH₃-C=N), 2.19 (s, 3H, CH₃), 6.28-7.87 (m, 18H, arom), 8.44 (s, 1H, NH); ¹³*C*-*NMR* (75 MHz) 21.5 (CH₃), 27.8 (CH₃), 107.0 (d, ¹*J*_{*PC*}=99.1 Hz, C-P), 116.8-158.4 (C-arom); ³¹*P*-*NMR* (120 MHz) 35.9; *IR* (*KBr*) 3194, 3052, 1715, 1501, 1441, 1098 cm⁻¹; *MS* (EI) 464 (M⁺, 100). Anal. Calcd for C₂₉H₂₅N₂SP: C, 75.00; H, 5.38; N, 6.03. Found: C, 75.11; H, 5.59; N, 5.91.

REFERENCES AND NOTES

- For excellent reviews see: a) Jones, G. in "Comprehensive Heterocyclic Chemistry". Katrizky, A. R.; Rees, C. W.; Potls, K. T.; Eds. Pergamon, Oxford, 1984, Vol. 2, p. 395. b) Grundon, M. F. in "Alkaloids Chemical and Biological Perspectives". Pelletier, S. W., Ed; Wiley, New York, 1988, Vol. 6, p. 339.
- For recent contributions see a) Fortunak, J. M. D.; Mastrocola, A. R.; Mellinger, M.; Sisti, N. J.; Wood, J. L.; Zhuang, Z. P. *Tetrahedron Lett.*, **1996**, *37*, 5679. b) Meller, J. M.; Merriman, G. D. Steroids, **1995**, *60*, 693.
- a) Reuhen, B. G.; Wittcoff, H. A. in "Pharmaceutical Chemicals in Perspective". Willey, New York, 1989. b) Koh, H. L.; Go, M. L.; Ngiam, T. L.; Mak, J. W. Eur. J. Med. Chem., 1994, 29, 107. c) Slater, A. F. Pharmacol. Ther., 1993, 57, 203.
- 4. Galanakis, D.; Calder, J. A. D.; Ganellin, C. R.; Owen, C. S.; Dunn, P. M. J. Med. Chem., 1995, 38, 3536.
- Ife, R. F.; Brown, T. H.; Keeling, D. J.; Leach, C. A.; Meeson, M. L.; Persons, M. E.; Reavill, D. R.; Theobald, C. J.; Wiggall, K. J. J. Med. Chem., 1992, 35, 3413. b) Ife, R. J. Drugs of the Future, 1992, 17, 796.

- a) Lanza, T. J.; Durette, P. L.; Rollins, T.; Siciliano, S.; Cianciasulo, D. N.; Kobayashi, S. V.; Caldwell, C. G.; Springer, M. S.; Hagman, W. K. J. Med. Chem., 1992, 35, 252. b) Campbell, Hardstone, J. D.; Palmer, M. J. J. Med. Chem., 1988, 31, 1031.
- 7. Kireev, D. B.; Chretien, J. R.; Raevsky, D. A. Eur. J. Med. Chem., 1995, 30, 395.
- 8. Sarges, R.; Gallagher, A.; Chambers, T. J.; Yeh, L. A. J. Med. Chem, 1993, 36, 2828.
- Toy, A. D. F.; Walsh, E. N. in "Phosphorus Chemistry in Everyday Living". American Chemical Society, Washington D. C., 1987. Engel, R. in "Handbook of Organophosphorus Chemistry". M. Dekker Inc., New York, 1992.
- For recent contributions see: a) Andersen, K. E.; Lundt, B. F.; Jørgensen, A. S.; Braestrup, C. Eur. J. Med. Chem., 1996, 31, 417. b) Galanakis, D.; Davis, C. A.; Del Rey Herrero, B.; Ganellin, C. R.; Dunn, P. M.; Jenkinson, D. H. Bioorg. Med. Chem. Lett., 1995, 5, 559. c) Lednicer, D.; Mitscher, L. A.; Georg, G. I. in "The Organic Chemistry of Drug Synthesis". Willey, New York, 1990, Vol. 4, p. 139.
- a) Pedersen, E. B. Tetrahedron, 1977, 33, 217. b) Saito, T.; Nakane, M.; Miyazaki, T.; Motoki, S. J. Chem. Soc. Perkin Trans 1, 1989, 2140. c) Flowers, N. T.; Haszeldine, R. N.; Owen, C. R.; Thomas, A. Chem. Commun., 1974, 134. d) Hester, J. B. J. Org. Chem., 1974, 39, 2137. e) Schweizer, E. E., Goff, S. D. V.; Murray, W. P. J. Org. Chem., 1977, 42, 200. f) Schäfer, H; Sattler, K; Gewald, K. J. Prakt. Chem., 1979, 321, 695. g) Okumura, K.; Adachi, T., Tomie, M.; Kondo, K.; Inowe, I. J. Chem. Soc. Perkin Trans I, 1972, 173. h) Capuano, L.; Urhahn, G.; Willmes, A. Chem. Ber., 1979, 112, 1012. i) Ghosez, L.; Sonveaux, E. J. Am. Chem. Soc., 1976, 95, 5417. j) Yamamoto, I.; Gotoh, T.; Minami, T.; Ohsiro, Y.; Ajawa, T. J. Org. Chem., 1974, 39, 3516.
- For recent contributions see: a) Palacios, F.; Pagalday, J.; Piquet, V.; Dahan, F.; Baceiredo, A.; Bertrand, G. J. Org. Chem., 1996, 000. b) Palacios, F.; Aparicio, D.; de los Santos, J. M. Tetrahedron, 1996, 52, 4123. c) Palacios, F.; Pagalday, J.; Ochoa de Retana, A. Heterocycles, 1995, 40, 543.
- a) Palacios, F.; García, J.; Ochoa de Retana, A.; Oyarzabal, J. Heterocycles, 1995, 41, 1915. b)
 López, F.; Pelaez, E.; Palacios, F.; Barluenga, J.; García, S.; Tejerina, B.; García, A. J. Org. Chem., 1994, 59, 1984.
- a) Palacios, F.; Aparicio, D.; de los Santos, J. M. Tetrahedron Lett., 1996, 37, 1289. b) Palacios, F.; Aparicio, D.; García J. Synlett, 1994, 260. c) Palacios, F.; Aparicio, D.; de los Santos, J. M. Tetrahedron, 1994, 50, 12727. d) Barluenga, J.; Merino, I.; Palacios, F. Tetrahedron Lett., 1990, 31, 6713. e) d) Barluenga, J.; Merino, I.; Palacios, F. Tetrahedron Lett., 1989, 30, 5493.
- a) Barluenga, J.; López, F.; Palacios, F. J. Organomet. Chem., 1990, 382, 61. b) Barluenga, J.;
 López, F.; Palacios, F. Chem. Commun, 1988, 1596. c) Barluenga, J.; López, F.; Palacios, F. Tetrahedron Lett., 1987, 28, 2875.
- 16. Palacios, F.; Aparicio, D.; García, J. Tetrahedron, 1996, 52, 9609.
- 17. Andrews, I. P.; Bannister, R.; Etridge, S. K.; Lewis, N. J.; Mullane, M. V.; Wells, A. S. *Tetrahedron Lett.*, **1995**, *36*, 7743.

(Received in UK 13 November 1996; revised 17 December 1996; accepted 19 December 1996)